Hi, I would like to briefly introduce Egetis Therapeutics, a Swedish biotech company and a candidate for the next catalyst play, and I am curious to hear your opinions on it.
I’m honestly surprised that almost nobody has this stock on their radar, and that you generally find so little about it. In September, Egetis has a PDUFA date coming up, and the prospects look promising to me:
On September 28, the FDA will decide on the US approval of Emcitate (Tiratricol) for the treatment of the rare MCT8 deficiency.
Emcitate has been approved in the EU since February 2025 as the first and so far only therapy for MCT8 deficiency.
In March 2026, the FDA also granted Priority Review to the marketing authorization application.Upon US approval, Egetis will receive a Priority Review Voucher.
In April 2026, there was a successful private placement of around 38 million USD (350 million SEK).
Actually, this is a classic candidate for a run-up and an approval bet, and in my opinion, Egetis has some good prerequisites here. Maybe it's just flying under the radar because the main trading venue is Nasdaq Stockholm.
How do you guys see this? Does anyone else have the stock in their portfolio or is watching it?